Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 15/20 | 0.50 |
| ▸ | RORC | P51449 | 1/20 | 0.42 |
| ▸ | PDE4A | P27815 | 2/20 | 0.40 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.40 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.40 |
| ▸ | APP | P05067 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5756225 | 0.92 | PDE4B (0.49) | PDE4BPDE4APDE4CPDE4DAPP | |
| SCHEMBL5756898 | 0.92 | PDE4B (0.47) | PDE4BRORC | |
| SCHEMBL5355151 | 0.90 | PDE4B (0.49) | PDE4BPDE4APDE4CPDE4DAPP | |
| SCHEMBL5362999 | 0.88 | PDE4B (0.53) | PDE4BPDE4APDE4CPDE4D | |
| SCHEMBL5752963 | 0.88 | PDE4B (0.53) | PDE4BPDE4APDE4CPDE4D | |
| SCHEMBL5756408 | 0.88 | PDE4B (0.53) | PDE4BPDE4APDE4CPDE4D | |
| SCHEMBL5355973 | 0.88 | PDE4B (0.56) | PDE4BPDE4APDE4CPDE4D | |
| SCHEMBL5359528 | 0.88 | PDE4B (0.56) | PDE4BPDE4APDE4CPDE4D | |
| SCHEMBL5368539 | 0.88 | PDE4B (0.51) | PDE4BPDE4APDE4CPDE4D | |
| SCHEMBL5350811 | 0.88 | PDE4B (0.51) | PDE4BPDE4APDE4CPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1242400-B1 | PYRROLIDINE DERIVATIVES AS CYCLIC AMP-SPECIFIC PHOSPHODIESTERASE INHIBITORS | ICOS CORP (US) | 2006-05-03 | — | — | EP | claimed |
| US-20060074123-A1 | Cyclic AMP-specific phosphodiesterase inhibitors | ICOS CORPORATION (US) | 2006-04-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060074123-A1 | Cyclic AMP-specific phosphodiesterase inhibitors | PDE4A, PDE4B, PDE7A | PDE4B 2/4885RORC 1678/4885PDE4A 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.